Status:
COMPLETED
Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections
Lead Sponsor:
The Center for Rheumatic Disease, Allergy, & Immunology
Collaborating Sponsors:
Grifols Therapeutics LLC
Conditions:
IgG Deficiency
Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
* This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency. * Will provide data for further collaboration in extending study to i...
Detailed Description
\*10 consenting adults (18 or older) will receive IgIV (Gamunex 10%) monthly at a dose of 400mg/kg body weight IV at 3ml/minute. Comprehensive labs will be monitored at each visit, as well as clinical...
Eligibility Criteria
Inclusion
- Adult (18 or older) with deficiency in one or more IgG subclasses with documented history of recurrent infections limited to upper or lower respiratory tract, urinary, and/or skin.
Exclusion
- Patients with panhypogammaglobulinemia or selective IgA deficiency.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00417573
Start Date
December 1 2004
End Date
December 1 2006
Last Update
January 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Rheumatic Disease, Allergy, Immunology
Kansas City, Missouri, United States, 64111